The“Chinese Expert Consensus on the Clinical Application of the Chinese Modified Triplet Combination with Irinotecan(CPT-11),Oxaliplatin(LOHP),Continuous Infusion 5-Fluorouracil,and Leucovorin for Colorectal Cancer”
结直肠癌改良三药cmFOLFOXIRI方案临床应用中国专家共识作者机构：Department of Medical OncologyThe Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhouGuangdongP.R.China Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor DiseasesGuangdong Institute of GastroenterologyThe Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhouGuangdongP.R.China 不详
出 版 物：《Gastroenterology Report》 (胃肠病学报道（英文）)
年 卷 期：2021年第9卷第4期
页 面：279-289,I0001页
核心收录：
学科分类：1007[医学-药学(可授医学、理学学位)] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：supported by The National Key Research and Development Plan of China[2019YFC1316003]
主 题：colorectal cancer FOLFOXIRI China expert consensus
摘 要：Colorectal cancer is the second most common malignant tumor in *** FOLFOXIRI regimen,which combines 5-fluorouracil/leucovorin,oxaliplatin,and irinotecan,is a high-intensity and highly effective chemotherapy ***,the original regimen is poorly tolerated in Chinese *** order to promote the standardization and rational application of FOLFOXIRI regimen by clinicians in China,the“Chinese Expert Consensus on the Clinical Application of the Chinese Modified Triplet Combination with Irinotecan(CPT-11),Oxaliplatin(LOHP),Continuous Infusion 5-Fluorouracil,and Leucovorin for Colorectal Cancerwas formulated by the Committee of Colorectal Cancer in Chinese Southwest Oncology *** on the mechanism underlying the combined three drugs and toxicity profile,the dosage of Chinese modified FOLFOXIRI(cmFOLFOXIRI)regimen and the management of adverse reactions are *** consensus recommended that the FOLFOXIRI regimen be used in neoadjuvant,conversion,and palliative therapy for colorectal cancer under specific *** consensus aimed to drive the application of cmFOLFOXIRI in the field of colorectal cancer in order to bring benefits to colorectal cancer patients.
维普期刊数据库